Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | TSPO | P30536 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | SCN1A | P35498 | 1/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29679671 | 1.00 | CTNNB1 (0.67) | CTNNB1MEN1KMT2ARAB9ATSPO | |
| Hydrochloric Acid SCHEMBL8136102 | 0.98 | CTNNB1 (0.65) | CTNNB1MEN1KMT2ARAB9ATSPO | |
| SCHEMBL9638920 | 0.94 | CTNNB1 (0.58) | CTNNB1MEN1KMT2ARAB9ATSPO | |
| SCHEMBL5708950 | 0.87 | LMNA (0.60) | CTNNB1MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL11604077 | 0.87 | CTNNB1 (0.51) | CTNNB1MEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL19524204 | 0.87 | SCN8A (0.53) | CTNNB1MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL4743129 | 0.87 | MAPT (0.62) | CTNNB1MEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL2303571 | 0.85 | MAPT (0.60) | CTNNB1MEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL7755868 | 0.85 | LMNA (0.51) | CTNNB1MEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL6857330 | 0.85 | CTNNB1 (0.54) | CTNNB1MEN1KMT2ARAB9ATSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016578-A1 | METHODS FOR ADDITIVELY MANUFACTURING MEDICAL DEVICES USING BIOGLASS FIBER REINFORCED POLYMERS | TU WIEN (AT) | 2024-01-18 | — | — | US | disclosed |
| CN-111905805-B | Eutectic solvent, carbon quantum dot, preparation method and application | 河北科技大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-109790148-B | Cyano-substituted heterocycles having USP30 inhibitor activity | 特殊治疗有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114174265-A | Substituted heterocycles as c-MYC targeting agents | 西北大学 | 2022-03-11 | — | — | CN | disclosed |
| EP-3844152-A1 | SUBSTITUTED HETEROCYCLES AS C-MYC TARGETING AGENTS | Northwestern University (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3519397-B1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-05-19 | — | — | EP | disclosed |
| EP-3519397-B1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-05-19 | — | — | EP | disclosed |
| US-10927110-B2 | Cyano-subtituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-10927110-B2 | Cyano-subtituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| WO-2020257261-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167378-A1 | Receptor Function Regulation Agent | GPR119, INSR, GPR88 | CTNNB1 3946/4885MEN1 4560/4885KMT2A 3747/4885 |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | CTNNB1 1524/4885MEN1 4495/4885KMT2A 3449/4885 |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | HRH2, HRH1, HRH4 | CTNNB1 4655/4885MEN1 3534/4885KMT2A 2733/4885 |
| US-10927110-B2 | Cyano-subtituted heterocycles with activity as inhibitors of USP30 | USP30, USP28, USP1 | CTNNB1 3045/4885MEN1 3369/4885KMT2A 2719/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | CTNNB1 1524/4885MEN1 4495/4885KMT2A 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.